| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 135.4 | 115.1 | 148.9 |
| Other income | 14.6 | 5.5 | 6.9 |
| Total income | 150.0 | 120.6 | 155.8 |
| Profit before exceptional items & tax | 33.7 | 25.1 | 23.3 |
| Profit before tax | 33.7 | 25.1 | 23.3 |
| Net profit | 25.2 | 18.9 | 17.7 |
| Operating margin | 22.5% | 20.8% | 15.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +42.40% |
|---|---|
| Net profit, quarter on quarter | +33.30% |
| Revenue, year on year | -9.10% |
BSE results filing, NSE: SYNCOMF. Figures extracted from the filing.
Syncom Formulation (India) Ltd: key numbers
- Share price
- ₹20.05
- Market cap
- ₹1,885 Cr
- Revenue (annual)
- ₹489.2 Cr
- Net profit (annual)
- ₹76.44 Cr
- P/E (TTM)
- 22.0×Sector 50.4×
- Promoter holding
- 50.57%+0.00% QoQ
- FII holding
- 0.35%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Syncom Formulation (India) Ltd
All →Syncom Formulation (India) Other Announcement
Syncom Formulations' promoters have voluntarily waived their right to the proposed final dividend of ₹0.10 per share. This waiver reduces total dividend payout obligations.
- Value
- ₹4.75 Cr
Syncom Formulation (India) Other Announcement
Syncom Formulations fixed 23 Sep 2026 as record date for a proposed 10% dividend (Rs.0.10/share) pending AGM approval. The 38th AGM is scheduled for 30 Sep 2026.
Syncom Formulation (India) Other Announcement
Syncom Formulations (India) Limited informed exchanges about the dispatch of letters to shareholders with unregistered email addresses, providing instructions to access the 38th AGM Notice and Annual Report.
Syncom Formulation (India) Annual General Meeting
Syncom Formulations (India) Limited issued notice for its 38th Annual General Meeting, scheduled for 30th September 2026 via Video Conferencing.
Syncom Formulation (India) Annual Report
Syncom Formulations (India) Limited has filed its 38th Annual Report for the financial year 2025-26, which includes the Notice for the upcoming Annual General Meeting.
Syncom Formulation (India) Q1 FY27 Results: Net Profit ₹24.8 Cr, Up 57.0% YoY
Syncom Formulation (India) Ltd reported revenue from operations of ₹125.5 Cr (+7.4% YoY) and net profit of ₹24.8 Cr (+57.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹24.8 Cr · +57.0% YoY